Risk factors for low lymphocyte count in patients with Type 2 Diabetes

Study identifier:CV181-102

ClinicalTrials.gov identifier:NCT01192659

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Identification of Risk Factors for Low Lymphocyte Count in Patients with Type 2 Diabetes: An Analysis of Data From the SAVOR Study

Medical condition

Diabetes Mellitus, Type 2

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

16492

Study type

Observational

Age

40 Years +

Date

Study Start Date: 01 May 2010

Primary Completion Date: 01 Dec 2015

Study Completion Date: 01 Dec 2015

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2016 by AstraZeneca

Collaborators

Bristol Myers Squibb

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Patients treated with saxagliptin or placebo Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.	-
Patients currently or previously on treatment Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.	-

Documents available

For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm
Download
CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Bristol-Myers Squibb